Coronary Artery Disease Prognosis and C-Reactive Protein Levels Improve in Proportion to Percent Lowering of Low-Density Lipoprotein

2006 ◽  
Vol 98 (1) ◽  
pp. 135-139 ◽  
Author(s):  
James H. O’Keefe ◽  
Loren Cordain ◽  
Philip G. Jones ◽  
Hussam Abuissa
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Disease Prognosis ◽  
Artery Disease

C-Reactive Protein Predicts the Severity of Coronary Artery Disease Beyond Low-Density Lipoprotein Cholesterol

Angiology ◽  
2011 ◽  
Vol 63 (3) ◽  
pp. 218-222 ◽  
Author(s):  
Hai-Hang Liu ◽  
Dong Zhao ◽  
Chang-Sheng Ma ◽  
Xiao-Hui Liu ◽  
Qiang Lv ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
C Reactive Protein ◽  
Low Density Lipoprotein Cholesterol ◽  
Reactive Protein ◽  
Artery Disease

Prospective studies and clinical trials have shown that C-reactive protein (CRP) independently predicts the occurrence of cardiovascular events, even in individuals without hypercholesterolemia. We evaluated whether CRP can predict the severity of coronary artery stenosis in patients with lower low-density lipoprotein cholesterol (LDL-C) levels. A total of 418 patients with lower LDL-C (<3.37 mmol/L) who underwent coronary angiography were recruited. The median levels of CRP increased according to the number of stenotic vessels. Multivariable adjustment model indicated that CRP was associated with the severity of coronary artery disease (CAD) in the top to the bottom third comparison of CRP levels, yielding an odds ratio of 1.72 (95% confidence interval: 1.08-2.74); this trend was preserved after excluding the confounding effect of statin treatment. C-reactive protein may serve as a useful biomarker for improving the risk assessment and secondary prevention of CAD patients without hypercholesterolemia.

Complement C3 and C-reactive protein levels in patients with stable coronary artery disease

2005 ◽  
Vol 94 (11) ◽  
pp. 1048-1053 ◽  
Author(s):  
Ramzi Ajjan ◽  
Timothy Futers ◽  
Jane Brown ◽  
Charlotte Cymbalista ◽  
May Boothby ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Fasting Glucose ◽  
Stable Coronary Artery Disease ◽  
Complement C3 ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
The Metabolic Syndrome ◽  
Artery Disease

SummaryThe aim of this study was to determine whether complement C3 is an indicator of coronary artery disease (CAD). We measured plasma C3 and CRP levels in 278 patients undergoing coronary angiography for typical symptoms of CAD and 269 healthy age and sex matched controls. C3 levels were significantly higher in patients compared with controls (1.15 g/l and 0.92 g/l respectively; p<0.001). In the patient group, C3 levels correlated with BMI, fasting glucose, HbA1c, fibrinogen, CRP and HDL in both men and women. CRP levels were also higher in patients compared with controls (1.14 mg/l and 0.86 mg/l respectively; p=0.005) and correlated with markers of the metabolic syndrome. In a logistic regression model including C3, smoking, hypertension, cholesterol and diabetes, C3 was independently associated with CAD with an odds ratio of 3.20 for a 1 SD increase in C3 levels. In contrast, CRP was not independently associated with CAD in a similar regression analysis. In conclusion, both C3 and CRP plasma levels are elevated in patients with symptoms of CAD. However, C3 seems to be a better indicator of CAD than CRP in this study, suggesting that C3 could be an additional marker for risk stratification in atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document